Your browser doesn't support javascript.
loading
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Li, Anna; Yang, Jin-Ji; Zhang, Xu-Chao; Zhang, Zhou; Su, Jian; Gou, Lan-Ying; Bai, Yu; Zhou, Qing; Yang, Zhenfan; Han-Zhang, Han; Zhong, Wen-Zhao; Chuai, Shannon; Zhang, Qi; Xie, Zhi; Gao, Hongfei; Chen, Huajun; Wang, Zhen; Wang, Zheng; Yang, Xue-Ning; Wang, Bin-Chao; Gan, Bin; Chen, Zhi-Hong; Jiang, Ben-Yuan; Wu, Si-Pei; Liu, Si-Yang; Xu, Chong-Rui; Wu, Yi-Long.
Afiliação
  • Li A; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Yang JJ; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Zhang XC; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Zhang Z; Burning Rock Biotech, Guangzhou, Guangdong Province, P.R. China.
  • Su J; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Gou LY; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Bai Y; Asia Innovative Medicines and Early Development, AstraZeneca, Shanghai, China.
  • Zhou Q; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Yang Z; Asia Innovative Medicines and Early Development, AstraZeneca, Shanghai, China.
  • Han-Zhang H; Burning Rock Biotech, Guangzhou, Guangdong Province, P.R. China.
  • Zhong WZ; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Chuai S; Burning Rock Biotech, Guangzhou, Guangdong Province, P.R. China.
  • Zhang Q; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Xie Z; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Gao H; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Chen H; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Wang Z; Asia Innovative Medicines and Early Development, AstraZeneca, Shanghai, China.
  • Wang Z; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Yang XN; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Wang BC; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Gan B; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Chen ZH; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Jiang BY; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Wu SP; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Liu SY; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Xu CR; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China. syylwu@live.cn.
Clin Cancer Res ; 23(16): 4929-4937, 2017 Aug 15.
Article em En | MEDLINE | ID: mdl-28396313
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-met / Neoplasias Pulmonares / Mutação Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas c-met / Neoplasias Pulmonares / Mutação Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article